Mr. McGahan brings more than two decades of executive leadership experience across the healthcare, pharmaceutical, and life sciences sectors, with a distinguished track record in corporate governance, compliance, and regulatory strategy. He most recently served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Spectrum Pharmaceuticals (NASDAQ: SPPI), where he guided the company […]
Chief Scientific Officer (CSO) Chuck Karan, PhD serves as Chief Scientific Officer of Nouveau Biosciences, where he oversees the company’s scientific platform from drug discovery through clinical development. Dr. Karan holds a PhD in Organic Chemistry from the University of Rochester and has built a distinguished career at the intersection of academia and biotechnology. At […]
Mr. Turgeon brings more than 38 years of experience in the pharmaceutical and biotechnology industries, with a career distinguished by leadership in oncology drug development, global sales and marketing, and product strategy. He most recently served as President, Chief Executive Officer, and Director of Spectrum Pharmaceuticals, where he successfully guided the company’s operations and strategic […]
Mr. Elmasri is a CPA and seasoned business professional with 20 years of experience in financial and management consulting. Mr. Elmasri began his career at PricewaterhouseCoopers(“PwC”) and worked on several of the firm’s Fortune 500 clients, primarily focused on the Life Sciences and Pharmaceutical industry. From PwC, he transitioned to lead advisory practices at boutique […]
Owen O’Connor is the Founder, Chair, and Chief Executive Officer of Nouveau Biosciences, where he has led the company’s evolution into a drug-focused biotechnology platform advancing novel nanotherapeutics for cancer. By integrating synthetic lethality screening, genomics, and computational biology, Nouveau has developed a pipeline of differentiated oncology therapies, including its lead candidate, Kromastat, which has shown […]